Eli Lilly to Initiate P-I Study of its Second Antibody Treatment Against COVID-19

 Eli Lilly to Initiate P-I Study of its Second Antibody Treatment Against COVID-19

Eli Lilly to Initiate P-I Study of its Second Antibody Treatment Against COVID-19

Shots:

  • Lilly’s partner Junshi has dosed the first healthy volunteer in a study evaluating JS016 to combat COVID-19. The study is being conducted by Junshi in China while Lilly to imminently initiate its P-I study in the US
  • Both P-I studies aim to evaluate the safety, tolerability, PK and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19. Lilly has exclusive rights in the ROW and will begin dosing patients in a complementary P-I study in the US imminently
  • The initiation of the clinical trial follows the P-I clinical study of LY-CoV555 which is currently being tested in hospitalized COVID-19 patients. Additionally, Lilly is planning to evaluate the efficacy of JS016 as both a monothx. and a combination with other Ab treatments in COVID-19 patients. The cocktails will include JS016 & LY-CoV555, as well as other Abs, currently in preclinical development

Click here to read full press release/ article | Ref: Eli Lilly | Image:  Pinterest

Related News: Eli Lilly and Junshi to Initiate Clinical Trials of COVID-19 Antibody in Q2’2020

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post